This article is more than 5 years old. Information may no longer be current.

Five important updates in sarcoma

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

The Sarcoma Foundation of America and Sarcoma Alliance last year petitioned to declare July as Sarcoma Awareness Month.

The organizations, which are making another petition this year, have vowed to raise awareness of the disease, as well as to encourage more research and drug development for what they characterize as a “forgotten cancer.”

In conjunction with the effort, HemOnc Today presents five updates in research and treatment.

• The FDA granted orphan drug designation to tazemetostat (Epizyme), a first-in-class EZH2 inhibitor, for the treatment of patients with soft tissue sarcoma. Read more.
• Single-agent aldoxorubicin (CytRX Corporation) — a novel albumin-binding prodrug of doxorubicin — appeared well tolerated and may improve outcomes compared with standard treatments for relapsed/refractory soft tissue sarcoma. Read more.
• Larotrectinib (LOXO-101, Loxo Oncology) — the first selective small-molecule pan-tropomyosin receptor kinase (TRK) inhibitor — demonstrated clinical activity in adults and children with various tumors that had neurotrophic tyrosine receptor kinase gene fusions. TRK gene fusions occur in more than 90% of rare cancers, including infantile fibrosarcoma. Read more.
• Treatment modifications that extended survival for childhood cancer survivors — including those with soft tissue sarcoma or bone sarcoma — during the past several decades also reduced incidence of serious chronic disease in these individuals later in life. Read more.
• The FDA granted orphan drug designation to ganitumab (AMG 479, NantCell) — a fully human monoclonal antibody directed against insulin growth factor-1R — for the treatment of Ewing sarcoma. Read more.